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Abstract
The identification of proteasome-generated spliced peptides (PSP) revealed a new unpredicted activity of the major cellular
protease. However, so far characterization of PSP was entirely dependent on the availability of patient-derived cytotoxic
CD8+ T lymphocytes (CTL) thus preventing a systematic investigation of proteasome-catalyzed peptide splicing (PCPS). For
an unrestricted PSP identification we here developed SpliceMet, combining the computer-based algorithm ProteaJ with in
vitro proteasomal degradation assays and mass spectrometry. By applying SpliceMet for the analysis of proteasomal
processing products of four different substrate polypeptides, derived from human tumor as well as viral antigens, we
identified fifteen new spliced peptides generated by PCPS either by cis or from two separate substrate molecules, i.e., by
trans splicing. Our data suggest that 20S proteasomes represent a molecular machine that, due to its catalytic and structural
properties, facilitates the generation of spliced peptides, thereby providing a pool of qualitatively new peptides from which
functionally relevant products may be selected.
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Introduction
The multiple subunit 20S proteasome is the central catalytic
unit of the ubiquitin proteasome system (UPS) and catalytic core of
the 26S proteasome that is built by the association of the two 19S
regulator complexes with the catalytic 20S core [19S-20S-19S].
With its N-terminal threonine residues as the single active site of
the b-subunits b1, b2 and b5, the 20S proteasome is a N-terminal
nucleophilic hydrolase responsible for the generation of the vast
majority of virus- or tumor-derived peptides presented by MHC
class I molecules at the cell surface for recognition by peptide-
specific cytotoxic T lymphocytes (CTL) [1,2]. This function is
generally aided by the interferon-c- (IFN-c)-induced synthesis of
the alternative catalytic subunits b1i, b2i, b5i, with concomitant
formation of immunoproteasome subtypes possessing altered
proteolytic properties as well as by the IFN-c-induced up-
regulation of the proteasome activator subunits PA28-a and
PA28-b [3,4]. Peptides generated by the 20S proteasome were so
far thought to exhibit a linear sequence identical to that found in
the unprocessed parental protein. This view was dramatically
changed by the identification of three epitope peptides derived
from the melanocyte protein gp100, the SP100 nuclear phospho-
protein and fibroblast growth factor (FGF-5), which represented
fusions of proteasomal cleavage products and were shown to be
generated by proteasomes [5–8]. Proteasome-catalyzed peptide
splicing was proposed to be a transpeptidation reaction whereby
the acylester intermediate is stabilized at the active site formed by
the N-terminal threonine of the catalytic subunits for a time span
that is sufficient to allow the N-termini of the released peptide
fragments to make a nucleophilic attack on the ester bond of the
acyl-enzyme intermediate thereby forming a new peptide bond
and producing the spliced peptides [6,9]. Under physiological
conditions proteolysis is normally favoured over hydrolysis.
Therefore the formation of new immunologically relevant MHC
class I ligands by proteasome catalyzed peptide splicing (PCPS)
was exciting and raised the possibility that reverse proteolysis may
be functionally more frequent and important than previously
thought. Nevertheless, as only three spliced epitope peptides had
been reported in the literature since their initial discovery in 2004
it was assumed that PCPS might rather be a rare event. It was also
emphasized, however, that presently available database search
algorithms fail to detect peptide splicing products [10]. Moreover,
the fact that identification of spliced peptides remained fortuitous
due to the dependence on the accidental availability of patient
derived CTLs so far prevented a systematic investigation of PSP.
It appears reasonable to assume that, similar to conventional
proteasomal cleavage products, not every spliced peptide will fulfil
the quality requirements of a MHC class I ligand. Thus,
considering the generation of spliced antigenic peptides recognized
by patient derived CTL, one might predict that the cellular
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proteasomal splicing reaction, as such, must be a considerably
more frequent event than so far assumed. But even if peptide
splicing is a rare event, PSP may still play a crucial role within the
immune response. This is due to the sensitivity of CTL cells, which
are able to detect very small numbers of MHC class I peptide
complexes [11], and in the most extreme example even a single
MHC class I complex [12].
To allow a systematic, CTL-independent investigation of PSP
we therefore developed SpliceMet: a method that combines
combinatorial computations (ProteaJ) with mass spectrometric
(MS) analyses of proteasome-generated peptides. Based on a given
protein or peptide sequence, ProteaJ produces a data set with the
m/z value of all theoretically possible PSP that may be generated
by the proteasome through the combination of any two fragments
(greater than one amino acid in length) generated from the same
substrate molecule (in cis) or from separate substrate molecules (in
trans) and ligated in a normal or reverse order. This is followed by
MS analysis of in vitro digests of the synthetic peptide substrate and
by comparison of the MS signals obtained with the theoretical
ProteaJ-computed m/z values. By matching the theoretical values
with the experimentally obtained m/z values and verifying the
peptide generation kinetics, a restricted list of candidate PSP is
generated. Their presence in 20S proteasome digests of substrates
is then investigated by LC-ESI-MS/MS and LC-MALDI-TOF/
TOF-MS/MS leading to the final identification of the PSP (Fig. 1).
Results
SpliceMet
The SpliceMet method is organized into two main experimental
blocks characterized by 7 main steps (Figure 1). To reduce the
number of possible proteasome generated spliced peptides (PSP)
the first block utilizes the following 4 main steps that are
subsequently investigated in the second block. The first experi-
mental block combines the computational algorithm ProteaJ with
proteasome in vitro digests of a synthetic peptide of choice and mass
spectrometric (MS) analyses as follows:
1) Calculation of all combinatorially possible PSP and
setting of the ProteaJ database. The digestion of the substrate
of length L with a sequence of amino acids ai, i = 1..L may result
in SCP~
1
2
L{Lextz1ð Þ L{Lextz2ð Þ cleavage products (PCP)
each of which can be denoted as PCPij, where the product starts at the
position i, i = 1…L-Lext+1 (C-terminus) and ends at the position
j = i+Lext-1…L (N-terminus). Lext describes the minimal length of a
PCP that can produce a PSP (here Lext = 2). Any two PCPij and
PCPkn may be spliced into PSPi-j/k-n. For the total amount of
generated products Sall, including PCP and PSP, we have i = 1…L-
Lext+1, j = i+Lext-1…L, k = 1…L-Lext+1, n = k+Lext-1…L and we
can calculate Sall~
PL{Lextz1
i~1
PL
j~izLext{1
PL{Lextz1
k~1
PL
n~kzLext{1
1. Note
that Sall~
1
4
L{Lextz1ð Þ2 L{Lextz2ð Þ2~S2PCP. PSP can be
classified into two main groups: cis splicing (PSPcis) and trans
splicing (PSPtrans), whereby cis splicing occurs in the same order as
in the substrate (PSPcis,normal, where i+Lext#j+1#k+1#n-Lext) or in
reverse order (PSPcis,reverse, k+Lext#n+1#i#j-Lext+1). The total
number of all PSP is then SPSP~
1
4
L{Lextz3ð Þ L{Lextz2ð Þ
L{Lextz1ð Þ L{Lextð Þ. The number of pure trans PSP can be
calculated as PSPtrans = SPSP-PSPcis,normal- PSPcis,reverse. Table 1
summarizes the conditions for each product and their total amount.
Estimation of mass-to-charge ratios (m/z) of all possible
PSP. To list all possible PSP, in which four indices ijkn define the
sequence, we computed the molecular weight (Mr, calc.) of each
peptide and the corresponding m/z values for charge states z = 1,
2, 3 (m/z = (Mr+z)/z). Since the m/z values of PSP can differ by
less than the mass accuracy of 0.5 Da for the used ESI-ion trap
mass spectrometer (LCQ-classic & DECA XP instruments), we
clustered all m/z values into groups with a m/z range of 0.2 Da
(accordingly to the MS instrument resolution). For each group we
determined the average m/z value thereby obtaining a set of
theoretical m/z values that could be further analyzed.
2) Matching with the LC-ESI/MS full spectra. The
presence of the theoretical m/z values was detected among MS
signals of the digestion products of the investigated peptide of choice.
3) Peak detection of all the computed m/z values. In the
LC-ESI mass chromatogram we identified the significant peaks for
each theoretical m/z value. For each theoretical m/z value either
no peak or several peaks could be detected and defined by their m/
z and retention time (RT).
4) Analysis of m/z time-dependent kinetics and
establishment of an inclusion list for the LC-ESI/MS
measurements. In time-dependent processing experiments
(signal intensity versus time of digestion) identified peaks that did
not fulfill the following criteria were eliminated from the candidate
list: i. initial intensity (t = 0) smaller than MAX (e.g. here = 107 for
measurements by DECA XP MAX instrument); ii. monotonously
ascending signal intensity towards a maximum followed by a
monotonous decline in case assay condition allowed re-entry of the
PSP. It was assumed that the monotonous increase resulted from
the continuous production of PSP and the decrease from the ‘‘re-
entry’’ event.
Next, we defined tmax as the digestion time when the highest
amount of generated PSP was observed and sorted all pairs (m/z,
RT) with respect to tmax into groups indexed as g of the size Dg. If
Dg.Dmax (here 15 depending on MS resolution) then the
corresponding group was split into subgroups gi of size smaller
than Dmax. The number of groups determined the number of
additional up-scaled processing assays in which the absolute
concentration of substrate and proteasome were increased keeping
the relative substrate/proteasome ratio constant, whereas the total
Author Summary
MHC class I molecules present antigenic peptides derived
from endogenously expressed foreign or aberrant protein
molecules to the outside world so that they can be
specifically recognised by cytotoxic T lymphocytes (CTLs)
at the cell surface. Responsible for the generation of these
peptides is the 20S proteasome, which is the major
proteolytic enzyme of the cell. These peptides were so far
believed to exhibit a linear sequence identical to that
found in the unprocessed parental protein. Using patient
derived CTL it was previously shown that by proteasome
catalyzed peptide splicing, i.e., by fusion of two protea-
some generated peptide fragments in a reversed proteol-
ysis reaction, novel spliced antigenic peptides can be
generated. To resolve the CTL dependence of spliced-
peptide identification we here performed experiments,
which combined mass spectrometric analysis of protea-
some generated peptides with a computer based algo-
rithm that predicts the masses of all theoretically possible
spliced peptides from a given substrate molecule (Splice-
Met). Using this unrestricted approach we here identified
several new spliced peptides of which some were derived
from two distinct substrate molecules. Our data reveal that
peptide splicing is an intrinsic additional catalytic property
of the proteasome, which may provide a qualitatively new
peptide pool for immune selection.
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number of subgroups represented the number of requested new
MS runs. The resulting m/z, RT, tmax established the inclusion list.
The second block consists of the following 3 steps:
5) LC-ESI-MS/MS analysis with inclusion list. Precursor
ion selection for MS/MS analysis was performed using the
established inclusion list enabling the fragmentation analysis of
even low-abundance peptides. MS/MS spectra were analyzed
with Bioworks software version 3.3 (Thermo Fisher) using the
ProteaJ database. Significant hits which were annotated as PSP
showed a peptide probability p,0.00005.
Figure 1. SpliceMet. Applying the computer program ProteaJ on a peptide sequence of choice, m/z values of all theoretically possible proteasomal
cleavage (PCP) and splicing (PSP) products are calculated (1st step). This is followed by an in vitro digest of the synthetic substrate and the comparison
of the obtained MS signals with the theoretical m/z values (2nd). Matching of the signals and verification of peptide generation kinetics results in an
inclusion list for LC-ESI-MS/MS analysis required for identification of the PSP (3rd, 4th). For final confirmation, the MS/MS spectra (5th) and the HPLC-
RT of proposed PSP (6th) are compared with those of the analogous synthetic peptides. For the identification of those PSP candidates that do not
fully satisfy these requisites, the generation of PSP is up-scaled followed by HPLC fractionation with an extended gradient and the fractions are
analyzed by nano-LC-MALDI-TOF/TOF-MS (7th).
doi:10.1371/journal.pcbi.1000830.g001
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6) Comparison with synthetic peptides. All identified PSP
resulting from step 5 were manually confirmed by comparison with
synthetic peptides of the same sequence. The candidate PSP and their
synthetic analogues had to exhibit a similar RT (delta RT,0.5 min)
and fragmentation pattern in the LC–ESI-MS/MS analysis.
7) Validation of PSP sequences by MALDI-TOF. In some
experiments the requirements outlined in step 5 and 6 were not
fully met requesting further MS identification. In this case, we
proceeded by fractionating the digestion products by reverse phase
(RP)-HPLC and by analyzing each fraction by LC-ESI-MS/MS
using an inclusion list with the m/z values of the PSP candidates.
Their RT in the HPLC run was also compared with that of the
corresponding synthetic peptides. Those fractions with MS/MS
and RT that matched the PSP were lyophilized and fractionated
again using a more focused HPLC method to decrease the number
of peptides in each fraction. The up-scaled fractions were
subsequently compared with the RT of the synthetic PSP and
analyzed by nano-LC-MALDI-TOF/TOF-MS/MS.
Validation of SpliceMet
For proof of principle we initially investigated 20S proteasome
catalyzed peptide splicing during proteasomal degradation of the
synthetic 13mer peptide (gp100PMEL1740–52, RTKAWNRQLYPEW),
previously shown to serve as substrate for PSP generation [6]. For the
experiments we used 20S proteasomes of Lymphoblastoid cell Lines
(LcL), which possess splicing activity [7] and predominantly resemble
the immunoproteasome subtype [13,14]. Following each step of
SpliceMet we obtained a progressive decrease of the number of
candidate PSP leading to the identification of the previously described
PSP gp100PMEL1740–42/47–52 [6] by LC-ESI/MS/MS at the 6
th step of
SpliceMet (Figure 2). The substantial reduction of PSP in the
candidate list (Table 2) and the final identification of the PSP
gp100PMEL1740–42/47–52 validated our analysis method.
To verify the hypothesis of the occurrence of a proteasome-
dependent trans splicing reaction we performed in vitro digestions in
which the unmodified 13mer gp10040–52 peptide was applied to
proteasomal processing in the presence of the same peptide but
with the heavy amino acid residues 13C6-Lys and
15N-Leu
(RTK+6AWNRQL+1YPEW). As shown in Figure 3, we indeed
detected PSP variants as being the results of cis (variants 2a & 2d)
or of trans (variants 2b & 2c) splicing, demonstrating that PCPS
can occur not only in cis but also in trans (see also Figure S1).
Identification of nine new PSP in the proteasomal
digestion of gp10035–57
By applying SpliceMet we investigated the generation of new
PSP derived from the proteasomal degradation products of the
23mer peptide gp10035–57, which is a N- and C- terminally
extended version of gp10040–52 by LcL 20S proteasome
(Figure 4A). In these experiments we identified eight new PSPcis,
four of which were identified at step 6 (Figure 4) and four at step 7
of SpliceMet (Table 3 & Figure S2). We also identified a ninth PSP
Table 1. Computation of cleavage and splicing products.
products conditions total amount
all fragments i = 1…L-Lext+1, j = i+Lext-1…L, k = 1…L-Lext+1, n = k+Lext-1…L 1
4
L{Lextz1ð Þ2 L{Lextz2ð Þ2
PCP i = 1…L-Lext+1 j = i+Lext-1…L 1
2
L{Lextz1ð Þ L{Lextz2ð Þ
cis - normal i = 1…L-2Lext j = i+Lext-1…L-Lext-1 k = j+2…L-Lext+1 n= k+Lext-1…L 1
24
L{2Lextz1ð Þ L{2Lextð Þ Lz3{2Lextð Þ Lz2{2Lextð Þ
cis - reverse k = 1…L-2Lext+1 n= k+Lext-1…L-Lext i = n+1…L-Lext j = i+Lext-1…L 1
24
L{2Lextz1ð Þ Lz4{2Lextð Þ Lz3{2Lextð Þ Lz2{2Lextð Þ
Described are the conditions to compute all products of a specific type (PCP, cis-normal PSP and –reverse PSP). The indices i, j, k and n are the amino acid positions of
the product, e.g. PSPi-j,k-n, L is the length of the substrate, Lext is the minimal length of a PCP that can produce a PSP.
doi:10.1371/journal.pcbi.1000830.t001
Figure 2. By applying SpliceMet we identified the known PSP produced by digestion of the synthetic 13mer gp10040–52 by 20S
proteasomes. Sequence of the substrate gp10040–52 and of the PSP gp10040–42/47–52 and its ESI-MS/MS spectrum (double protonated with m/z
610.8) are shown. In the spectra B- and Y-ions are reported. Ions’ loss of water is symbolized by u. In the experiments (100 ml of reaction) 4 nmol of
gp10040–52 were cleaved for 36 hours by 1 mg 20S proteasome purified from LcL.
doi:10.1371/journal.pcbi.1000830.g002
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with the sequence [VSRQL][VSRQL] derived from splicing of
two distinct molecules of the PCP gp10035–39 (Figure 5). The
identification of this PSP was of particular relevance because it was
the first example of PSPtrans detected in in vitro proteasomal
digestion of a single peptide sequence.
PSP formation is a general phenomenon not restricted to
the gp10035–57 sequence
Since the sequence requirement for PCPS are not yet known
one might argue that the observed frequent PSP generation
when gp100PMEL1735–57 was used as substrate was due certain
gp10035–57 sequence specificities. To test this we applied
SpliceMet for the analysis of PSP derived from another
polypeptide sequence of the same protein, i.e. gp100201–229.
Among the proteasome-generated degradation products of this
29mer we identified three PSP (Table 4 and Figure S3). Since
peptide fragments with overlapping sequences were spliced
together these PSP were generated by a trans splicing event.
In order to exclude a peculiar and rare tendency of the entire
gp100 sequence to be spliced by PCPS we investigated the in vitro
digestion products of two other peptides, i.e. the 30mer HIV-
derived gag-pol29–58 and the murine cytolomegalovirus (MCMV)-
derived 25mer polypeptide pp8916–40. The in vitro processing of
gag-pol29–58 by proteasomes produced at least one PSPtrans (Table 4
& Figure S4), whereas two PSPtrans were detected after the
digestion of the MCMV derived pp89 polypeptide peptide (Table 4
& Figure S5).
Discussion
SpliceMet
The aim of our study was to develop a method for the
identification of spliced peptides which would allow the identifi-
cation of any theoretically possible PSP and which was
independent of adventitiously available CD8+ T cells and T-cell
recognition assays permitting the detection of only a single spliced
epitope peptide. The availability of such a method would greatly
facilitate systematic studies required to elucidate the molecular
mechanism of PCPS. Therefore we have developed and applied a
method – SpliceMet – that, by combining computational and
experimental methods, facilitates the identification of proteasome-
generated spliced peptides.
Although in this investigation we have considered only
polypeptide substrates up to a length of 30 amino acid residues,
SpliceMet could also be applied to longer peptides or proteins to
further our understanding of the mechanisms that govern PCPS
and, in particular, trans-splicing. It has to be pointed out
however that an increase in substrate length will lead to an
exponential expansion of the ProteaJ data base as well as the
number of peaks detectable by MS and therefore will require
the application of restricting parameters such as size or sequence
quality to match this approach with the capacity of the presently
available MS technologies.
In our experiments we observed a substantial number of peak
spectra at the 5th step of SpliceMet, which could not be
identified with sufficient confidence due to the low MS/MS
quality. The number of unidentified spectra depends on the size
of the ProteaJ database and to technical difficulties of MS
analysis. Therefore, to reduce the number of unidentifiable
spectra we incorporated the 7th step into our method. Indeed,
up-scaling of the digestion products by two rounds of HPLC
fractionation permitted a better separation of the digestion
products thereby limiting the number of overlapping peptides
with similar m/z and RT and increased product concentration
in this manner facilitating the identification of PSP by MS.
Furthermore, at step 7 we analyzed the sample with a second
MS instrument, a MALDI-TOF/TOF mass spectrometer,
which has a higher resolution and sensitivity than the used
ESI-ion trap mass spectrometer. Its application in other studies
allowed the identification of peptides not previously detected by
ESI-MS/MS, not only because of the higher sensitivity but also
due to the different method of ionization and detection, which
led to the identification of a complementary pool of peptides
[15,16]. Accordingly, we used both techniques to identify as
many PSP as possible. LC-ESI/MS analysis was primarily
adopted because it is a less time consuming technique and
allowed the analyses of as large a number of samples as needed
at SpliceMet step 4. Likely, a further minimization of
unidentified spectra could be obtained by exploiting the high
performance of the new generations of MS analyzers.
The computational algorithm ProteaJ is based on a combina-
torial approach. Therefore the amount of calculated PSP strongly
depends on parameters like substrate length L and the minimal
length of a PCP Lext, as well as the kind of PSP allowed, i.e. cis or
trans PSP. Thus ProteaJ parameter settings were used which in
preliminary experiments seemed to be most reliable; for example,
we limited the PCP Lext to a minimum of 2 and accordingly we
identified PSP such as gp10047–48/35–39 or gag-pol45–57/48–49. In
contrast, when we considered PCP Lext = 1 in a preliminary
experiment on gp10035–57 we were not able to identify any new
PSP (data not shown).
SpliceMet applications and PSP implications
By applying SpliceMet we here showed that 20S proteasomes
possess a substantial in vitro splicing activity. Since in vitro
experiments for generation of spliced and non-spliced epitope
Table 2. PSP candidate reduction by applying SpliceMet.
number of m/z number of sequences
SpliceMet steps 1 2 3 4 5 6 7
gp10040–52 2580 (100) 280 (10.8) 32 (1.2) 18 (0.7) 2 1
gp10035–57 7229 (100) 1288 (17.8) 1121 (15.5) 239 (3.3) 20 4 5
Reduction of number of PSP candidates during the progression of SpliceMet step by step. The number of possible PSP detectable in the in vitro digestion of a peptide declines
continuously during the consecutive steps of SpliceMet (Figure 1). Here the PSP number reduction observed for the 13mer gp10040–52 and 23mer gp10035–57 is reported both
as total number and as a percentage compared to the theoretical PSP number (in brackets). The values are referring to the number of possible PSP at the end of the SpliceMet
step. For example, although 5664 PSP could be generated from gp10040–52 assuming 2 as the minimum length of the native PCP (Lext), only 2580 represent the m/z value
clusters (obtained with a cluster range of 0.2) that will be matched with the LC-ESI/MS full spectrum at the beginning of step 2. Moreover, up to step 4 the numbers are referred
to as the number of m/z values whereas from step 5 they are referred to as the possible sequence because they have been identified by MS/MS.
doi:10.1371/journal.pcbi.1000830.t002
Proteasomal Splicing Discovered by SpliceMet
PLoS Computational Biology | www.ploscompbiol.org 5 June 2010 | Volume 6 | Issue 6 | e1000830
peptides are known to closely resemble the in vivo situation [3] our
data reveal that 20S proteasomes represent a molecular machine
that facilitates the generation of spliced peptides from its own
cleavage products. Therefore, our data may have considerable
biological implications in that they provide evidence that
proteasome-dependent protein degradation results in the genera-
tion of a second, so far undetected pool of spliced peptides, from
which novel potentially functionally relevant peptides can be
selected. Indeed, the two previously identified PSP were shown to
be MHC class I epitopes recognized by CTL of human patients
[6,7]. This and the relatively high number of PSP that we
identified raises the possibility that peptide splicing in general may
lead to an increase in the peptide pool available for epitope
selection. For example, from the melanocytic gp100PMEL17 tumor
antigen (661 amino acids) 1,786,862 9mers with a unique
sequence could be theoretically produced. Of these, a maximum
of 652 are unspliced proteasomal cleavage products while the rest
(99.96%) represent theoretical PSP. At the moment we do not
have any sufficient information to judge on how many of these
PSP (as well as normal PCP) are really produced and which
percentage of them may efficiently bind MHC class I molecules.
Based on our preliminary data we are tempted to speculate that
specific PCP are generated more efficiently than PSP even if the
MS signal of some PSP (e.g. gp10047–55/35–39) was as high as that of
many PCP (data not shown). Nevertheless, if, for example PCP
were produced 1000-fold more efficiently than any given PSP,
spliced peptides generated from gp100PMEL17 would still represent
a significant peptide pool (i.e. the 73.26% of the 9mers derived
Figure 3. Generation of PSP by proteasomal trans splicing. (A) To demonstrate the generation of a PSPtrans by the binding of two fragments
originated from two distinct molecules of substrate, 5 nmol gp10040–52 and its heavy analogue with amino acids
13C6-Lys and
15N-Leu
(RTK+6AWNRQL+1YPEW) were digested together for 36 hours by 1.5 mg LcL 20S proteasomes in 100 ml buffer. Theoretically four different PSP could
be generated from the cis or trans ligation of the proteasomal fragments [RTK] and [QLYPEW] with sequences [RTK][QLYPEW]: gp10040–42/47–52-a,
[M+H]+ = 1220.7; gp10040–42/47–52-b, [M+H]+ = 1221.7; gp10040–42/47–52-c, [M+H]+ =1226.7; gp10040–42/47–52-d, [M+H]+ = 1227.7. (B) LC-MALDI-TOF/
TOF-MS spectra at RT = 41.3 min show peaks which can be assigned to all four possible PSP of gp10040–42/47–52 (for MS/MS spectra see Figure S1).
doi:10.1371/journal.pcbi.1000830.g003
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from the digestion of gp100PMEL17) from which antigenic spliced
peptides could be selected.
This basic computational analysis assumes that the splicing of
proteasomal cleavage products can occur also in vivo. Our observation
that the in vitro splicing reaction not only occurs in cis but also in trans
indirectly supports such an assumption. The existence of the trans PSP
implies the likely situation that two or more substrate molecules are
present at the same time within the proteasomal cavity as suggested
by some excellent previous studies [17–19] or that the cleavage
products of a first substrate molecule remain within the catalytic
chamber while a second molecule of substrate is cleaved. Very
recently, Dalet and co-workers investigated trans proteasome splicing
in vivo, providing some very interesting albeit not final insights. They
showed that PSPtrans were generated in vivo when the precursor
peptides of FGF-5 and gp100 were electroporated into COS cells,
whereas only the FGF-5-derived PSPtrans (and in a very small amount)
could be detected by CTL assay when COS cells were transfected
with FGF-5 or gp100 plasmid [8]. Taking into account the high
number of PSPtrans we identified within in vitro digestion products of
four peptides, we are led to conclude that further studies in vitro and in
vivo on different cellular and proteasome models are required to
clarify this phenomenon.
An extensive application of SpliceMet on a wide range of
polypeptides substrates would also help to identify putative peptide
sequence motifs that facilitate the proteasomal splicing reaction.
For example, in seven of the nine gp10035–57-derived PSP, the
sequence VSR represents the N-terminus of those PCP, which
according to the transpeptidation model [6,20] perform a
nucleophilic attack on the acyl-enzyme intermediate, thereby
forming the detected PSP. Likewise, for four PSP the sequence
YPEW represents the C-terminus, which forms the acyl-enzyme
intermediate that is subsequently attacked by the second PCP
generating the new PSP. From these observations one might infer
a higher affinity of these two peptide sequences for a transpep-
tidation reaction. However, only a more extensive investigation of
this specific issue with SpliceMet, covering a large number of
different polypeptides would allow to validate such a hypothesis.
For this and other aims, studies performed with the help of
SpliceMet could be powered if coupled with algorithms for the
prediction of proteasomal cleavages, mathematical modeling of
degradation kinetics as well as of the MHC class I antigen
presentation [21–26]. Such an approach would also facilitate the
reduction of the theoretical PSP number, which might represent a
limitation of SpliceMet application to very long proteins such as
gp100PMEL17. By combining the SpliceMet results with the estimation
of these and other algorithms it would be theoretically possible to
restrict the PSP identification to a group of PSP possessing features of
interest (e.g. epitope-specific for a defined HLA I haplotype) and to
predict their altered expression upon proteasome modification [24].
Methods
I. Peptides and peptide synthesis
All peptides were synthesized using Fmoc solid phase chemistry as
previously described [27]. Exception had to be made for heavy
analogues of gp10040–52. The isotope-labeled amino acids
15N-
Fmoc-L-Leucine (3eq. amino acid, 3eq. HBTU, 6eq. DIEA in DMF)
and L-Lysine-a-N-Fmoc, e-N-T-Boc, 13C6 (1.92eq. amino acid,
1.92eq. HBTU, 3.84eq. DIEA in DMF) were coupled over night.
The sequence enumeration for the peptides gp10040–52, gp10035–57
and gp100201–229 is referred to the human gp100
PMEL17 sequence
described by Adema and colleagues [28], for the peptide pp8916–40 is
referred to the murine cytomegalovirus pp89 protein described by
Lyons et al. [29]. The peptide sequence here named gag-pol29–58 is a
modified version of the sequence 29–57 of the HIV gap-pol protein as
described by Reitz et al. [30], where a Valin was inserted before the
Threonin 53. All peptide sequences were extrapolated on the web site
http://www.uniprot.org/.
Figure 4. Identification of PSP in gp10035–57 digestion by SpliceMet [step 6]. (A) Sequence of gp10035–57. The bracket indicates the
previously described substrate gp10040–52. Arrows indicate the cleavage positions that are necessary to generate the newly identified PSP. The colors
correspond to the identified PSP sequences as reported in (B) to (E). (B–E) LC-ESI/MS/MS spectra (upper panels) and extracted ion chromatograms
(middle and lower panels) of the double-protonated PSP. (B) [QLYPEWTEA][VSRQL] (gp10047–55/35–39) -m/z 860.4, (C) [QLYPEWTEA][RTK] (gp10047–55/40–42) -
m/z 761.6, (D) [YPEW][VSRQL] (gp10049–52/35–39) – m/z 589.5, (E) [YPEW][VSR] (gp10049–52/35–37) – m/z 469.0. The RT of the detected peaks in the digestion is
consistent (with a maximum difference of 0.5 min) with those of synthetic peptide of same sequences (lower panel of extracted ion chromatograms).
40 mM gp10035–57 were digested for 24 hours in 100 ml reaction by 0.5 mg 20S proteasomes purified from LcLs.
doi:10.1371/journal.pcbi.1000830.g004
Table 3. PSP identified in the proteasomal digestion of the polypeptide gp10035–57.
Peptide (gp100) Sequence Mr, calc PSP type
Identification step of
SpliceMet
49–52/35–39 [YPEW][VSRQL] 1176.59 cis,reverse 6
49–50/35–37 [YPEW][VSR] 935.45 cis,reverse 6
47–55/40–42 [QLYPEWTEA][RTK] 1520.76 cis,reverse 6
47–55/35–39 [QLYPEWTEA][VSRQL] 1718.86 cis,reverse 6
47–52/35–37 [QLYPEW][VSR] 1176.59 cis,reverse 7
47–48/35–39 [QL][VSRQL] 842.50 cis,reverse 7
45–52/35–37 [NRQLYPEW][VSR] 1446.74 cis,reverse 7
37–38/49–57 [RQ][YPEWTEAQR] 1462.70 cis,normal 7
35–39/35–39 [VSRQL] [VSRQL] 1184.70 trans 7
The PSP identified by the application of SpliceMet on the proteasome-mediated digestion of the substrate gp10035–57 are here described. PSPnormal or PSPreverse result
from splicing in the same order as the substrate or in reverse order to the substrate, respectively. PSPcis are derived from the splicing of two non-overlapping sequences
of the original substrate. In contrast, PSPtrans necessarily originate from two distinct substrate molecules because of the overlapping sequences of the two peptides
spliced together.
doi:10.1371/journal.pcbi.1000830.t003
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II. Cell cultures
Lymphoblastoid cell lines (LcLs) are human B lymphocytes
immortalized with Epstein Barr virus (EBV) which mainly express
active immunoproteasomes [13,14]. LcLs were cultured in
RPMI1640 medium supplemented with 10% FCS.
III. 20S proteasome purification
20S proteasomes were purified from 3*E+09 LcLs as previously
reported [31]. The purity of 20S proteasome preparation was
verified by SDS-PAGE electrophoresis (12, 5% poly-acrylamide
gel stained with Coomassie dye) (Figure S6). Furthermore, a non-
proteasome proteolytic activity of the preparation was tested and
excluded (data not shown) by the digestion of 40 mM gp10040–52
for 24 hours by 1 mg of LcL 20S proteasomes in presence of
400 mM Lactacystin (previously incubated with 20S proteasomes
at room temperature for 10 min).
IV. In vitro digestion of synthetic peptide substrates
Synthetic peptides at different concentrations (from 40 to
100 mM) were digested by 0.25–1.5 mg 20S proteasomes in 50–
100 ml Hepes buffer (Hepes 20 mM, KCl 1 mM, MgCl 0.5 mM,
DTT 1 mM, NaN3 1 mM, pH 7.3) for different time periods
(from 20 min to 48 hours) at 37uC. Digestions were stopped by
acidic inactivation and frozen. Digestions were performed also in
TEAD buffer (Tris 20 mM, EDTA 1 mM, NaN3 1 mM, DTT
1 mM, pH 7.2) and no remarkable differences compared to Hepes
buffer emerged (data not shown). In contrast, for SpliceMet step 7,
1.1 mmol of the peptides (at the final concentration of 100 mM)
were digested for 24 hours by 62 mg of LcL 20S proteasomes in
10 ml Hepes buffer and the products up-scaled by RP-HPLC
separation. All experiments reported in this study were repeated at
least twice and each set of experiments was measured by each MS
instrument at least twice.
V. LC-ESI MS
In LC-runs the peptide separation was carried out on a 2.1 mm
(mRPC C2/C18, 100 mm62.1 mm, 3 mm, 120 A˚, Amersham)
and a 1 mm RP column (Beta Basic-18, 100 mm61 mm, 3 mm,
150 A˚, ThermoFisher) using a Surveyor system (ThermoFisher
Scientific, USA). The mobile phase (A) was 100% water
containing 0.05% (v/v) TFA and (B) was 70:30 (v/v) acetoni-
trile/water containing 0.045% (v/v) TFA or 0.1% acetic acid for
the PSP identifications reported in Figure 3. Online MS analysis
was performed by DECA XP MAX iontrap instrument (Thermo-
Fisher Scientific, USA) and by LCQ-classic iontrap (ThermoFisher
Scientific, USA) after HPLC separation (HP1100, Agilent). MS
data were acquired with a triple scan method in positive ion mode
(MS - mass range 250–2000 m/z, zoom scan, MS/MS). Analysis
Figure 5. MS/MS identification of the PSPtrans gp10035–39/35–39
[VSRQL][VSRQL] within the gp10035–57 digestion products.
MALDI-TOF/TOF-MS/MS spectrum of precursor ion [M+H]+ = 1185.7
observed in the up-scaled digestion (see ‘‘Methods’’ section) of the
23mer gp10035–57 by 20S LcL proteasomes (upper panel) is shown in
comparison with the synthetic peptide [VSRQL][VSRQL] (lower panel). In
the spectra B-, Y-ions, the loss of ammonia symbolized by *, the relative
abundance (%) in y-axis and m/z in the x-axis. are reported.
doi:10.1371/journal.pcbi.1000830.g005
Table 4. PSP identified in proteasomal digestions of three additional polypeptides.
PSP Sequence Mr, calc PSP type
Identification step of
SpliceMet
substrate gp100201–230- AHSSSAFTITDQVPFSVSVSQLRALDGGNK
201–204/201–209 [AHSS][AHSSSAFTI] 1301.60 trans 6
201–209/201–207 [AHSSSAFTI][AHSSSAF] 1607.70 Trans 7
201–207/201–207 [AHSSSAF][AHSSSAF] 1393.61 trans 7
substrate gag-pol29–58 - YKLKHIVWASRELERFAVNPGLLEVTSEGC
45–57/48–49 [AVNPGLLEVTSEG][PG] 1439.58 trans 6
substrate pp8916–40 – RLMYDMYPHFMPTNLGPSEKRVWMS
27–30/23–30 [PTNL][PHFMPTNL] 1381.61 trans 6
27–32/20–30 [PTNLGP][DMYPHFMPTNL] 1943.89 trans 6
To verify that the relatively high PSP number was not peculiar to the sequence gp10035–57 we extended our investigation to three additional peptides. Six new PSP were
identified within their products of in vitro proteasomal digest by applying SpliceMet. Three of them derived from the digestion of the sequence gp100201–230, one from
HIV gag-pol29–58 and two from MCMV pp8916–40. All of them were produced by a trans splicing reaction.
doi:10.1371/journal.pcbi.1000830.t004
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of ESI/MS data was accomplished using Bioworks version 3.3
(ThermoFisher Scientific, USA). Database searching was per-
formed using the ProteaJ database and the following parameters:
no enzyme, mass tolerance for fragment ions 1amu. In time-
dependent processing experiments (signal intensity versus time of
digestion) we analyzed the kinetics of the identified peaks by using
LCQuan software version 2.5 (Thermo Fisher). At step 3 of
SpliceMet the significant peaks for each theoretical m/z value in
the LC-ESI mass chromatogram were identified by Bioworks
peak detection algorithm with a signal-to-noise ratio larger than d
(here = 2).
VI. Digestion product up-scaling by RP-HPLC
Further identification of the PSP at step 7 of SpliceMet was
performed by MALDI-TOF/TOF-MS analysis of the gp10035–57
digestion products separated by two distinct rounds of RP-HPLC.
In the first round 57 fractions were collected, lyophilized and
analyzed by LC-ESI/MS to identify PSP candidates. The fractions
containing the PSP candidates were then separated with more
focused gradients (different for each selected fraction of the first
round of HPLC separation) on the same column obtaining 47
fractions, which were lyophilized and investigated by MALDI-
TOF/TOF-MS analysis. Each round was obtained by collecting
the eluted fractions of the 5-15 runs (5–20 ml each) to maintain a
good separation of the digestion products on the chromatogram.
The runs were carried out on the column C18 (3364.6 mm;
ODS1 1.5 mm) by the HPLC Beckman SytemGold and different
gradients of acetonitrile.
VII. Nano-LC-MALDI-TOF/TOF-MS
Peptide separation was carried out using an Ultimate HPLC
system (Dionex, Idstein, Germany). Samples were concentrated on
a trap column (PepMap C18, 5 mm6300 mm65 mm, 100 A˚,
Dionex) and eluted onto an analytical column (PepMap C18,
150 mm675 mm63 mm, 100 A˚, Dionex). The mobile phase (A)
was 2:98 (v/v) acetonitrile/water containing 0.05% (v/v) TFA and
(B) was 80:20 (v/v) acetonitrile/water containing 0.045% (v/v)
TFA. Runs were performed at a flow rate of 200 nL/min using a
binary gradient 0–15% B in 4 min, 15–60% B in 45 min, 60–
100% B in 5 min. Column effluent was mixed with MALDI
matrix (5 mg/ml a-cyano-4-hydroxy-cinnamic acid in 70:30 (v/v)
acetontrile/water containing 0.1% (v/v) TFA, 1 ml/min) and
spotted at ten second intervals on MALDI steel targets using a
Probot fractionation device (Dionex). MS analysis was performed
on a 4700 Proteomics Analyzer (Applied Biosystems, Framing-
ham, MA, USA). MS data were acquired in positive ion mode in
the mass range 800–4000 m/z by accumulation of 1200 laser shots
per spot and processed with default calibration. MS/MS spectra
were generated by 1 keV collisions and accumulation of 2500 to
10000 laser shots. Analysis of MALDI MS data was accomplished
using MASCOT version 2.1 (Matrixscince, London, UK).
Database search was performed using ProteaJ database and the
following parameters: no enzyme, mass tolerance for precursors,
+/2 80 ppm and for MS/MS fragment ions, +/2 0.3 Da.
Spectral images for manual validation were prepared with Data
Explorer Software version 4.8 (Applied Biosystems).
Supporting Information
Figure S1 Verification of the PSP gp10040–42/47–52 with
sequence RTKQLYPEW generated by cis and trans splicing.
Found at: doi:10.1371/journal.pcbi.1000830.s001 (0.97 MB TIF)
Figure S2 MS/MS identification of four gp10035–57 PSP at step
7 of SpliceMet.
Found at: doi:10.1371/journal.pcbi.1000830.s002 (0.55 MB TIF)
Figure S3 Identification of three PSP originated from the
synthetic substrate gp100201–230.
Found at: doi:10.1371/journal.pcbi.1000830.s003 (0.90 MB TIF)
Figure S4 Identification of the PSP gag-pol45–57/48–49.
Found at: doi:10.1371/journal.pcbi.1000830.s004 (0.34 MB TIF)
Figure S5 Identification of two PSP originated from the
synthetic substrate pp8916–40.
Found at: doi:10.1371/journal.pcbi.1000830.s005 (0.63 MB TIF)
Figure S6 SDS-PAGE Electrophoresis with 20S proteasome
purified from LcLs.
Found at: doi:10.1371/journal.pcbi.1000830.s006 (0.95 MB TIF)
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